Advanced
Product
Solutions
Partners
Resources
Company
Toggle menu
Home
/
Advagene Biopharma
Advagene Biopharma
Overview
Locations
Financials
Operating Metrics
Human Capital
Key People
Competitors
Supplier Risk
Advagene Biopharma
Stock Price
NT$23.9
2024-10-29
Market Capitalization
NT$1.4 B
2024-10-29
Advagene Biopharma Summary
Company Summary
Overview
Advagene Biopharma is a company that researches, develops, and distributes vaccine products. Its products include nasal spray influenza (LT-Flu), allergy vaccines (LT-Allergy), COVID-19 immunotherapy drug AD17002-SC, etc.
Type
Public
Status
Active
Website
http://www.advagene.com.tw
Cybersecurity rating
Sectors
Healthcare
distribution
drug development
medtech
Homepage
Table of Contents
Financials
Competitors
Advagene Biopharma Financials
Summary Financials
Net income (FY, 2025)
(NT$68.3M)
Cash (FY, 2025)
NT$55.3M
EBIT (FY, 2025)
(NT$70.9M)
Enterprise value
$1.4B
Competitors and Similar Companies
Cadent Therapeutics
Healthcare - Private
Jiangsu Hengrui Medicine
Healthcare - Public
Ambee Pharmaceuticals
Healthcare - Private
Delta-Fly Pharma
Healthcare - Public
Compare competitors
Footer menu
Contact us
Product
Intelligence Suite
Supplier Intelligence Platform
Craft Intelligence Portal
Craft API
Craft for Teams
Supplier Intelligence Platform
Craft Alerts
Craft N-Tier Mapping
Craft Risk Hub
Chrome extension
Solutions
Supplier Intelligence
Sales Intelligence
Aerospace and Defense
Resources
Resource center
Blog
Company
About
Careers
Contact
Terms of Service
Privacy Policy
Security
© Craft.co 2026
Share price data provided by IEX
Back
to top